狄诺塞麦价格

Clinical treatment methods for bone metastases are limited, and systemic treatment is difficult to control. Moreover, most of them are osteolytic bone metastases, and bone destruction is difficult to reconstruct. The most important treatment is regular intravenous administration of bisphosphonates once a month. A subcutaneous injection drug with better anti-bone metastasis effect than traditional bisphosphonates - (Xgeva, denosumab), also known as denosumab. The drug has been approved by the FDA and is included in NCCN guidelines.

Denosumab's mechanism of action: RANKL is a transmembrane or soluble protein that plays an important role in the formation, function, survival and cells responsible for bone resorption of osteoclasts, regulating the release of calcium from bone. Through RANKL stimulation, osteoclast activity is enhanced, mediating the occurrence of bone metastasis bone pathology in solid tumors. Denosumab can bind to the RANKL protein, preventing RANKL from binding to the receptor RANK expressed on the surface of osteoclasts, precursor cells, and osteoclast-like giant cells to activate subsequent malignant processes, thus exerting an anti-bone metastasis effect. 

Denosumab is currently approved for three indications: (1) Prevention of bone-related events in bone metastases from solid tumors, except for patients with multiple myeloma. Instructions for use: 120mg, once every 4 weeks. Also infuse calcium or vitamin D to prevent hypocalcemia. (2) Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications. Instructions for use: 120 mg, once every 4 weeks. In the first month of treatment, add 120 mg on the 8th and 15th days respectively. (3) Hypercalcemia in bisphosphonate-resistant malignant tumors. The usage method is the same as the second indication. 

  In terms of price, although denosumab has been launched in China, due to various reasons, it is not accessible to patients and the price is unknown. In the United States, denosumab is expensive and most patients cannot afford it. The good news is that the price in Turkey is the lowest: the 125mg specification is only about $3,000, which is extremely cost-effective.